Fact.MR has announced the addition of the “Spinal Bulbar Muscular Atrophy Treatment Market: Global Industry Analysis and Opportunity Assessment, 2018 to 2028"report to their offering.
Rockville, MD -- (SBWIRE) -- 10/02/2018 -- Spinal and bulbar muscular atrophy is also called Kennedy disease. It is a disorder of the nerve cells that control muscle movement. These nerve cells are present in the brainstem. Spinal and bulbar muscular atrophy mainly occurs in males, and is characterized by atrophy that usually arises in adulthood. Spinal and bulbar muscular atrophy results in cramping and leg muscle weakness. The bulbar muscles are also affected, which causes disruptive problems regarding swallowing and speech. Fasciculation's, unusual breast development, and infertility are also observed in this disorder. Spinal bulbar muscular atrophy has been diagnosed in the U.S., Europe, Asia, South America, and Australia. The Japanese population is shown to have a very high occurrence. There is no known cure for spinal bulbar muscular atrophy. Physical therapy, occupational therapy, and speech therapy are usually used to maintain individual skills. Braces and wheel chairs are used for ambulation. For breast reduction physicians prefer surgery.
Spinal Bulbar Muscular Atrophy Treatment Market: Drivers and Restraints
The growing number of incidences of spinal bulbar muscular atrophy is driving the growth of the market. Rapid turnaround time and lower cost of this procedure over conventional methods are also fueling the growth of the spinal bulbar muscular atrophy treatment market. A reimbursement process is also available in many regions like the U.S., Europe, and Japan. However, the global market for spinal bulbar muscular atrophy treatment is expected to be deterred by the limited number of drugs available that inhibits in hormone level on the market. Dutasteride and leuprolide are two drugs which are currently present around the world for spinal bulbar muscular atrophy treatment.
You can Get Free Sample Report Here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1221
Spinal Bulbar Muscular Atrophy Treatment Market: Segmentation
Tentatively, the spinal bulbar muscular atrophy treatment market has been segmented on the basis of drug class and distribution channel.
Based on drug class, the spinal bulbar muscular atrophy treatment market is segmented as:
5?-Reductase Inhibitors (5-ARIs)
Gonadotropin-releasing Hormone (GnRH) Agonists
Based on distribution channel, the spinal bulbar muscular atrophy treatment market is segmented as:
Ambulatory Surgical Centers
Spinal Bulbar Muscular Atrophy Treatment Market: Overview
The occurrence rate of spinal bulbar muscular atrophy is around 1 per 100,000 individuals, and high incidences are observed in Finland. From the 2005–2006 National Health and Nutrition Examination Survey using a sample of 1480 men with a mean age of 53.2 years (range 37–79) with spinal bulbar muscular atrophy disorder were obtained for the hormonal profile, healthy control mean values and standard errors and according to the Oxford University Press, in 2006 a study followed 223 Japanese spinal bulbar muscular atrophy patients for a number of years, and among them, 15 died, with a median age of 65 years. A common cause of death for spinal bulbar muscular atrophy patients was pneumonia and respiratory failure. The increasing number of patient visits for spinal bulbar muscular atrophy treatment and the growing demand for the same exhibit lucrative growth opportunity for companies investing in the spinal bulbar muscular atrophy treatment market.
Visit For TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1221
Spinal Bulbar Muscular Atrophy Treatment Market: Regional Outlook
A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa. North America is expected to represent huge contribution under spinal bulbar muscular atrophy treatment by revenue generation. Quickened development on the improvement of new items and high spending on innovative work in Europe demonstrates the elevation of the spinal bulbar muscular atrophy treatment market. With ascending in standards of health care services and increase in mindfulness towards the medications in India and China is relied upon to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area.
Spinal Bulbar Muscular Atrophy Treatment Market: Key Players
Some of the players identified in the spinal bulbar muscular atrophy treatment market include GlaxoSmithKline plc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Century Pharmaceuticals Ltd, Johnson & Johnson, Astellas Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH, and Sanofi.